On Monday, the fascinating conclusion to a lengthy court battle between Swiss drugmaker Novartis (NYSE:NVS) and the Supreme Court of India was revealed. The court ruled that Novartis' top-selling blockbuster drug Glivec (which is branded as Gleevec in the U.S.) should not be granted patent protection, which means that generic competitors can continue manufacturing their own versions of the drug in India. As the debate continues over the long-term implications of this controversial decision, investors are wondering how this ruling actually impacts Novartis' sales. In the following video, health care analyst Max Macaluso discusses the effect of this decision on Novartis' top line.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.